Immunological Responses and Long-Term Treatment Interruption after Human Immunodeficiency Virus Type 1 (HIV-1) Lipopeptide Immunization of HIV-1-Infected Patients: the LIPTHERA Study*†

Gilles Pialoux,1,5* Romina P. Quercia,1 Hanne Gahery,2 Nathalie Daniel,3 Laurence Slama,1 Pierre-Marie Girard,4 Philippe Bonnard,1 Willy Rozenbaum,1,5,6 Véronique Schneider,1 Dominique Salmon,3 and Jean-Gérard Guillet2†

APHP, Tenon Hospital, Paris, France1; Cochin Institute, INSERM U567, Paris, France2; APHP, Cochin Hospital, Paris, France3; APHP, Saint-Antoine Hospital, Paris, France3; Université Pierre et Marie Curie, Paris, France2; and APHP, Saint-Louis Hospital, Paris, France6

Received 18 April 2007/Returned for modification 2 September 2007/Accepted 19 December 2007

We studied the time course of immunological and virological markers after highly active antiretroviral therapy (HAART) interruption in chronically human immunodeficiency virus type 1 (HIV-1)-infected patients immunized with an HIV lipopeptide preparation. In a prospective open pilot study, 24 HIV-1-infected HAART-treated patients with undetectable plasma viral loads (pVLs) and CD4+ T-cell counts above 350/mm3 were immunized at weeks 0, 3, and 6 with a candidate vaccine consisting of six HIV lipopeptides. At week 24, patients with pVLs of <1.7 log10 copies/ml were invited to stop taking HAART. Antiretroviral therapy was resumed if the pVL rose above 4.47 log10 copies/ml and/or if the CD4+ T-cell count fell below 250/mm3. Immunological and virologic parameters were studied before and after HAART interruption. The median baseline and nadir CD4+ T-cell counts were 482 (interquartile range [IQR], 195 to 826) and 313 (IQR, 1 to 481)/mm3, respectively. New specific CD8+ T-cell responses to HIV-1 epitopes were detected after immunization in 13 (57%) of 23 assessable patients. Twenty-one patients were evaluated 96 weeks after HAART interruption. The median time to pVL rebound was 4 weeks (IQR, 2 to 6), and the median peak pVL was 4.26 (IQR, 3 to 5) log10 copies/ml. Thirteen of these 21 patients resumed HAART a median of 60 weeks after immunization (IQR, 9.2 to 68.4 weeks), when the median pVL was 4.8 (IQR, 2.9 to 5.7) log10 copies/ml and the median CD4+ T-cell count was 551 (IQR, 156 to 778)/mm3. Eight patients were still off therapy at 96 weeks, with a median pVL of 4 (IQR, 1.7 to 4.6) log10 copies/ml and a median CD4+ T-cell count of 412 (IQR, 299 to 832)/mm3. No clinical disease progression had occurred. Despite the lack of a control arm, these findings warrant a randomized study of therapeutic vaccination with HIV lipopeptides followed by long-term HAART interruption in AIDS-free chronically infected patients.

Highly active antiretroviral therapy (HAART) limits human immunodeficiency virus type 1 (HIV-1) replication and drastically reduces AIDS-related morbidity and mortality (35). However, HAART is not universally available, must be taken for life, and has clinical and/or metabolic adverse effects in 40 to 60% of patients.

Long-term HAART increases the number of naive immune T cells and improves the functional status of CD4+ and CD8+ T cells (31). However, HAART also drives the production of HIV antigens below the threshold required to efficiently stimulate HIV-specific T-cell effectors or HIV-specific naive cells (24). Approaches aimed at enhancing anti-HIV immunity include adoptive therapy, cytokine therapy, and therapeutic immunization combined with structured treatment interruption (STI) (6, 17).

Therapeutic immunization has the potential to improve immunologic control of HIV and, possibly, to permit at least temporary discontinuation of antiretroviral therapy. In chronically infected patients with full suppression of HIV replication by antiretroviral therapy, STI has been proposed as a strategy to conserve active drugs, reduce treatment costs, and avoid adverse effects. Evaluation of therapeutic vaccines for HIV infection has been hindered by the lack of surrogate markers of protective or beneficial HIV-specific immunity in patients with chronic infection (11, 33, 39). Therapeutic immunization has so far proven disappointing (2, 5, 7, 14–16, 18, 20, 25–29, 36, 44, 47) and is not currently recommended (4, 8, 9, 13, 42, 50), but immunization with an HIV lipopeptide vaccine combined with a recombinant canarypox vaccine (ALVAC-HIV1) and interleukin-2 (IL-2) before HAART cessation contributed to controlling viral replication in chronically HIV-1-infected patients (19).

Lipopeptides are promising vaccine components. In a randomized phase I trial, we showed that a mixture of six HIV-1 lipopeptides was well tolerated and induced HIV-specific B-cell and T-cell responses in healthy volunteers (3, 21, 38).

The aims of the LIPTHERA study were the following: (i) to evaluate lipopeptide immunogenicity in HIV-1-infected patients and (ii) to examine if lipopeptide immunization permits long-term STI.

MATERIALS AND METHODS

Immunization protocol and study design. This was an open phase II pilot vaccine trial. Twenty-four patients meeting the following inclusion criteria were...
selected in two clinical centers: asymptomatic chronic HIV-1 infection for at least 18 months, 18 years of age or more, at least 1 year of HAART, and HIV RNA levels of <1.7 log_{10} copies/ml and CD4+ T-cell count of >350/mm³ for at least 6 months. Patients were excluded if (i) they had received cytokines, immunomodulatory therapy, or other candidate HIV vaccines or (ii) they were pregnant or had a serious illness at enrollment. The study took place in the following three phases: an immunization phase (LIPTHERA I), a treatment interruption phase (LIPTHERA II), and a long-term follow-up phase (LIPTHERA III). The study was approved by our institutional ethical review board (CCPRPB), and all patients gave their written informed consent.

In LIPTHERA I, 24 patients received three intramuscular injections of a six-lipopeptide mixture (three Nef, two Gag, and one Env lipopeptide) at 0, 3, and 6 weeks and continued antiretroviral treatment until week 24 (W24). In LIPTHERA II (starting at W24 after the last immunization), patients with HIV RNA levels of <1.7 log_{10} copies/ml were invited to stop taking HAART. HAART was resumed, after at least 1 month of interruption, if the CD4+ cell count fell below 250/mm³, the plasma viral load (pVL) was >4.47 log_{10} copies/ml on two consecutive occasions, or a major illness occurred. In LIPTHERA III, patients at W0, W2, W6, W10, W20, and W24, every 2 months until W52, and routinely thereafter. Blood samples were also collected 14 days after each injection to measure immunogenicity.

HIV-1 RNA genotyping was performed at W4 and W8 after HAART interruption. After HAART interruption (W24), genotyping was performed on viral RNA as pVL was undetectable. Proviral HIV DNA was extracted from peripheral blood mononuclear cells (PBMCs), and the RT and protease genes were amplified as previously described (37). Only mutations associated with antiretroviral resistance were considered (22).

The main end point was the percentage of patients who developed new HIV-specific CD4+ and/or CD8+ T-cell responses. A new T-cell response was defined as a positive specific T-cell response that was absent before immunization (W0). Secondary end points were the clinical and biological tolerability of vaccination and the subsequent immunological and virological outcome.

The lipopeptide vaccine is a mixture of six large HIV-1 peptides derived from Nef, Gag, and Env amino acid sequences, modified by the addition of a palmitoyl-histaminamide group, as described elsewhere (21). Three lipopeptides were derived from the HIV LAI Nef protein and were designated L-N1 (Nef amino acids [aa] 66 to 97), L-N2 (Nef aa 117 to 147), and L-N3 (Nef aa 182 to 205); two lipopeptides were derived from the HIV LAI Gag protein and were designated L-G1 (Gag aa 183 to 214) and L-G2 (Gag aa 253 to 284); and one lipopeptide, designated L-E (Env aa 303 to 335), was derived from the HIV BX08 strain.

**Laboratory methods.** Immunological parameters were measured in the 24 patients at W0, W2, W4, W5, and W24. T-cell proliferative responses were determined prior to (W0) and after each vaccine injection with PBMCs purified using standard methods (12, 13, 20). Briefly, PBMCs or CD4+ or CD8+ T cells (10⁶ cells/well) were cultured in medium alone (negative control) or with 1 μg/ml of one of the soluble large peptides similar to those used in the vaccine mixture (N1, N2, N3, G1, G2, and E). Proliferation was determined on day 7 by adding 1 μCi/well of [³H]thymidine. The results are reported as a stimulation index, calculated as the ratio of the level of proliferation with the peptide (in counts per minute) to proliferation without the peptide. The proliferative response was considered positive if the stimulation index was >3 (21).

HIV-1-specific CD8+ T cells producing gamma interferon were measured with an ex vivo enzyme-linked immunospot assay (21). Briefly, PBMCs (10⁶/well) were stimulated with CD8+ T-cell epitopes appropriate for each patient’s HLA class I molecules. An average of 18 (range, 2 to 34) HIV-1 peptides were tested per patient. Numbers of spot-forming cells (SFCs) were normalized to 10⁵ PBMCs and averaged from duplicate wells. The number of specific SFCs per 10⁶ PBMCs was calculated by subtracting the negative control value from the experimental SFC count. A CD8+ T-cell response was considered significant when (i) a minimum of 100 SFCs/10⁶ PBMCs were present per well, (ii) this number was ≥2 times that obtained with the negative control (PBMCs alone), (iii) the number of SFCs in stimulated wells (with peptide) minus the number of SFCs in unstimulated wells was ≥100/10⁶ PBMCs, and (iv) this was true for both duplicate wells as described elsewhere (21, 51). Patients with new HIV-specific CD4+ or CD8+ T-cell responses were considered vaccine responders.

**Statistical analysis.** SAS software, version 8.2, for Windows (SAS Institute, Inc., Cary, NC) was used for all statistical analyses. The chi-square test or Fisher’s exact test was used to compare categorical variables.

---

**RESULTS**

**Characteristics of patients.** Twenty-four HAART-treated asymptomatic HIV-1-infected patients with CD4+ T-cell counts of ≥350/mm³ and plasma HIV RNA levels of <1.7 log_{10} copies/ml were enrolled in the study. They had received a median of four lines of ART (interquartile range [IQR], one to seven lines) when they stopped taking HAART. During LIPTHERA I, 8 patients (33.5%) received two nucleoside reverse transcriptase inhibitors (NRTIs) plus one protease inhibitor (PI) and 16 patients (66.5%) received two NRTIs plus one nonnucleoside reverse transcriptase inhibitor.

The median baseline and nadir CD4+ T-cell counts were 629/mm³ (IQR, 397 to 1,132) and 313/mm³ (IQR, 1 to 481), respectively. The nadir CD4+ T-cell counts were stratified as follows: 200 to 350 cells/mm³, 13 patients (54.2%); >350 cells/mm³, 7 patients (29.2%); and <200 cells/mm³, 4 patients (16.6%). The median total time on ART was 37.2 months (range, 20.4 to 63.6 months). All patients received the full vaccination schedule of three injections. Three patients were withdrawn from the study at W24 because their viral loads exceeded 1.7 log_{10} copies/ml (Tables 1 and 2).

**Tolerability and safety.** No serious adverse events occurred during the vaccination period. Pain and induration at the injection site were the most common adverse events (n = 10). Eight patients reported asthenia and four reported fever after vaccination.

---

**TABLE 1. Baseline characteristics of patients**

| Parameter | Value |
|-----------|-------|
| No. of patients | 24 |
| Median (range) age (yr) | 35.8 (28.3–55.1) |
| Gender (no. [%]) | Female 18 (75) |
| | Male 35.2 |
| CDC status (%) | A 54.2 |
| | B 33.3 |
| | C 12.5 |
| Median (range) time for primary ARV (yr) | 3.5 (1.9–8.7) |
| Median (range) time of HIV serology at time of first ARV (yr) | 3.4 (0–10.2) |
| No. (%) of patients receiving HAART during the trial | Two NRTIs + PI 8 (33.5) |
| | Two NRTIs + nonnucleoside RT inhibitor 16 (66.5) |
| Median (range) CD4+ cell count before immunization (cells/mm³) | 629 (397–1132) |
| Median (range) nadir CD4+ cell count (cells/mm³) | 313 (1–481) |
| No. (%) of patients with median plasma HIV RNA of <1.7 log_{10} copies/ml | 24 (100) |
| Median (range) antiviral therapy duration (wk) | 3.1 (1.7–5.3) |
| Median (range) CD4+ cell count at treatment interruption (cells/mm³) | 722 (383–1029) |
| No. (%) of patients with median plasma HIV RNA of <1.7 log_{10} copies/ml at treatment interruption | 21 (87.5) |

---

The Kaplan-Meier method was used to evaluate the risk of HAART resumption. Since few subjects remained off treatment at the end of the study, multivariate analyses were performed separately for CD4+ T-cell and viral load variables. Student’s t test or the Wilcoxon test was used to compare continuous variables. The correlation between the CD4+ T-cell nadir and the time off therapy was evaluated with Pearson’s correlation coefficient test and Student’s t test. All values are given as medians, and all viral load values are log_{10} values unless otherwise specified. P values of <0.05 were considered significant.
TABLE 2. Virological and immunological parameters at treatment interruption and follow-up

| Parameter | Value |
|-----------|-------|
| No. of patients with HIV RNA load of $<1.7 \log_{10}$ copies/ml at wk 24/total no. of patients (%) | 21/24 (87.5) |
| Median (range) peak HIV RNA load (log$_{10}$copies/ml) | 4.26 (3–5) |
| Median (range) time to peak HIV RNA load (wk) | 4 (2–6) |
| No. of patients who resumed HAART at wk 24/total no. of patients | 13/21 |
| Median (range) delay in resuming therapy (wk) | 60 (9,2–68.4) |
| Median (range) CD4 cell count at time of restarting therapy (cells/mm$^3$) | 551 (156–778) |
| Median (range) HIV RNA load at time of resuming therapy (log$_{10}$copies/ml) | 4.8 (2.9–5.7) |
| Median (range) time to achieve undetectable pVL after resuming HAART (wk) | 8 (4–16) |
| Median (range) CD4 cell count at W96 in patients not resuming treatment (cells/mm$^3$) | 412 (299–832) |
| Median (range) HIV RNA load at W96 in patients not resuming treatment (log$_{10}$copies/ml) | 4 (1.7–4.6) |

After HAART interruption (LIPTHERA II), eight, five, and four patients had asthenia, monomorphic herpes zoster reactivation, and an HIV serosconversion-like syndrome, respectively. The latter syndrome occurred a median of 4 weeks (range, 1 to 6 weeks) after HAART interruption, and all four patients concerned resumed HAART without reaching the pVL and median time to pVL rebound after HAART interruption was 8 (4–16) weeks. The rest resumed HAART after W63 (70%), and these responses were detected on at least two occasions in 5/23 (22%) patients.

Anti-HIV immunological responses and CD4$^+$ T-cell proliferative responses. Twenty-three of the 24 patients had interpretable T-cell responses to at least one of the six HIV-1 large peptides. At baseline (W0), 30% of the patients (7/23 patients) responded to at least one of the six peptides, compared to 74% of patients (17/23 patients) after the three vaccine injections. These responses were detected at least twice during the study in 11/23 patients (48%). New T-cell responses to at least one large peptide were detected after vaccination in 16/23 patients (70%), and these responses were detected on at least two occasions in 5/23 (22%) patients.

CD4$^+$ T-cell responses were directed mainly to the Gag 2 peptide, as described in detail elsewhere (51).

Lymphoproliferative responses to HIV-1 peptides, either before or after immunization, did not significantly influence the probability of remaining off HAART (data not shown).

CD8$^+$ T-cell responses. Six (26%) of 23 assessable patients had CD8$^+$ T-cell responses to HIV-1 epitopes at baseline, and 13/23 patients (57%) had new responses after vaccination. These new responses were detected on at least two occasions in 8/23 patients (35%). Among the 13 patients with new CD8$^+$ T-cell responses, 4, 4, 2, and 3 patients had new responses to one, two, three, and four peptides, respectively. Most of the CD8$^+$ T-cell epitopes recognized in vaccinated patients were located in the G2, N1, and N2 peptides, as in healthy volunteers (21).

Outcome after HAART interruption. The dynamics of HIV replication were evaluated for 96 weeks in 21 patients. The median time to pVL rebound after HAART interruption was 4 weeks (IQR, 2 to 6 weeks), with a median peak pVL of 4.26 (IQR, 3 to 5) log$_{10}$ copies/ml. Forty-eight weeks after HAART interruption, 9/21 patients (43%) were still off therapy, all with pVLs of $<4.47 \log_{10}$ copies/ml ($<4 \log_{10}$ copies/ml in 4 patients). Seven of these nine patients had new CD4$^+$ or CD8$^+$ T-cell responses after vaccination.

Thirteen of the 21 patients resumed HAART after a median interval of 60 weeks (IQR, 9.2 to 68.4 weeks), with a median pVL of 0.8 (2.9 to 5.7) log$_{10}$ copies/ml and a median CD4$^+$ T-cell count of 551/mm$^3$ (range, 156 to 778/mm$^3$). Eight patients were still off HAART at 96 weeks, with a median pVL of 0 (IQR, 1.7 to 4.6) log$_{10}$ copies/ml and a median CD4$^+$ T-cell count of 412 (IQR, 299 to 832)/mm$^3$. Interestingly, one of these eight patients had an undetectable pVL ($<50$ copies/ml) at W96 (Table 2; Fig. 1).

Impact of nadir CD4$^+$ T-cell count on outcome after HAART interruption. The kinetics of HIV resumption was biphasic. Almost half of the patients resumed HAART between W8 and W12, and the rest resumed HAART after W63 (64 to 68 weeks).

Eight patients were still off therapy at 96 weeks. The median time to HAART resumption in the remaining 13 patients was 60 weeks (IQR, 9.2 to 68.4 weeks) (Fig. 2a). The median baseline CD4$^+$ T-cell counts in these 8 and 13 patients were 617 (IQR, 397 to 832)/mm$^3$ and 648 (IQR, 447 to 1,132)/mm$^3$, respectively (Table 1; Fig. 1).

Thirteen patients resumed HAART, with a median CD4$^+$ T-cell count of 551 (156 to 778)/mm$^3$. The median count at treatment interruption for patients who remained off therapy was 412 (IQR, 299 to 832)/mm$^3$ at W96. Only 4 of the 21 assessable patients had a nadir CD4$^+$ T-cell count above 350 cells/mm$^3$, and 5 of the 8 patients who remained off therapy at 96 weeks had a CD4$^+$ T-cell nadir of between 200 and 250/mm$^3$.

Kaplan-Meier analysis showed a trend toward a relation between a CD4$^+$ T-cell nadir of 200/mm$^3$ and the risk of HAART resumption (Fig. 2b).

The nadir CD4$^+$ T-cell count correlated with the CD4$^+$ T-cell count slope during treatment interruption ($r = 0.72; P = 0.007$).

DISCUSSION

This study shows that HIV-1-specific T-cell responses can be induced by lipopeptide vaccination of chronically infected patients on HAART. The efficacy of the lipopeptide vaccine used in this study was first tested in HIV-seronegative volunteers in an open phase I study called VAC 04 (21, 38), in which T-cell proliferative responses were detected in 25/26 subjects (92%) and CD8$^+$ T-cell responses were detected in 19/22 subjects (86%).

Structured treatment interruption has been explored as a means of offsetting the complexity and toxicity of antiretroviral treatment, and also the development of viral resistance (6, 23, 34, 46). Previous reports suggest that CD4$^+$ T-cell counts are predictive of the outcome after treatment discontinuation (29, 36, 44, 45), even if HAART interruption consistently leads to a fall in the CD4$^+$ T-cell count and to pVL rebound (10, 28, 30, 49).

In the present study, new CD4$^+$ T-cell proliferative responses to at least one HIV-1 large peptide were detected after
vaccination in 16/23 patients (70%), and new CD8+ T-cell responses were detected in 13/23 patients (57%). Ninety percent of the 23 immunized patients developed CD4+ and/or CD8+ responses to at least one HIV-1 peptide.

Functional alterations and impaired maturation of HIV-1-specific CD4+ and CD8+ T cells have been shown to correlate with disease progression. The rationale of therapeutic immunization for HIV infection is based on studies suggesting that cytotoxic T lymphocytes are involved in controlling HIV-1 replication and also that CD4+ T-cell proliferative responses (essentially to p24) correlate with better control of HIV-1 viremia. The reversible cell-mediated immune deficits associated with chronic HIV-1 infection have important implications for immunotherapy (35). In this study, the aim of therapeutic immunization was to induce new HIV-1-specific CD4+ T cells and also to induce new HIV-1-specific CD8+ T cells in patients with chronic infection, as is the case in long-term nonprogressors (40, 51).

Levy et al. (30) randomized HIV-1-infected patients to continue with their antiretroviral regimen, either alone or combined with four injections of the ALVAC-HIV (vCP1433) and Lipo-6T vaccines, followed by three cycles of IL-2. Proliferative responses to p24 antigen remained stable in 47% of patients (15/34 patients) in the vaccine–IL-2 group, compared with 24% (8/33 patients) of controls (P = 0.049). After stopping HAART, 24% of the patients in the vaccine–IL-2 group lowered their viral set point, compared to 5% of controls (P = 0.027), suggesting that immunization before HAART cessation might contribute to controlling viral replication. In contrast, no significant difference in the time before resuming therapy was found between the two groups (median, 54 versus 69.5 days; P = 0.11). In the Vacciter study, 79% of patients resumed therapy after a median of 6.3 weeks (IQR, 5.9 to 7.1 weeks) (25). Harrer et al. reported that therapeutic vaccination with recombinant HIV-1 nef-expressing modified vaccinia virus Ankara gave similar results: 8/14 patients resumed HAART after a median treatment interruption of 15 weeks (range, 4 to 37 weeks) (25). Molina et al. examined whether intermittent IL-2 therapy could defer antiretroviral (ARV) therapy in ARV-naive HIV-1-infected patients. The patients were randomized to receive IL-2 (n = 66) or no treatment (n = 64). ARV therapy was deferred by a median of 48 weeks in the IL-2 arm (P = 0.02), and at W96, 35% of subjects in the IL-2 arm versus 59% of patients in the control group had experienced treatment failure, defined as a CD4 cell count of <300/mm³, ARV initiation, or the occurrence of an AIDS-defining event or
death. Moreover, treatment failure was significantly more rapid in the control arm. In naive patients with a baseline CD4 cell count between 300 and 500/mm³, IL-2 administration substantially deferred the initiation of ARV without affecting HIV replication (32). In the TILT pilot study, involving a total of 86 ARV-experienced patients, the use of IL-2 before ARV interruption prolonged the time off ARV. Ninety-six weeks after ARV interruption, 66% of control patients had resumed ARV therapy, compared with only 34% of IL-2-treated patients (1). The different trials of candidate vaccines with and without IL-2 are not comparable, however, because of different inclusion and exclusion criteria and different schedules of vaccination and follow-up. It is nonetheless noteworthy that in the LIPIHERA trial, treatment resumption was necessary after a median of 60 weeks (range, 9.2 to 68.4 weeks) for only 62% of patients. In the case control study by Molina et al., IL-2 deferred ARV therapy for 48 weeks. The LIPIHERA trial provides proof of concept for treatment-experienced patients that therapeutic vaccination can defer the resumption of ARV treatment. In a retrospective cohort study involving 105 patients, 57% of patients had not resumed therapy a median of 114 weeks after immunization (43). In a recent study (ACTG A5086) of STI in 167 HIV-infected patients with preserved immune function, Skiest et al. found that only 46/167 patients (27.5%) resumed HAART at week 96 (43), but it is noteworthy that the baseline CD4⁺ cell count was higher than that for the LIPIHERA study population (833/mm³ [668 to 989] versus 629/mm³ [132 to 397]). The best predictor of the CD4⁺ T-cell decline and of the risk of resuming ARV therapy was the nadir CD4⁺ T-cell count, as in other studies (27, 29, 32, 46, 50). Treatment interruption in patients with a pre-ARV CD4⁺ cell count nadir above 200/mm³ was not associated with adverse events.

In conclusion, this study shows that a significant percentage of chronically HIV-1-infected patients can remain off antiretroviral drug therapy for long periods after vaccination with a mixture of six HIV lipopeptides.

ACKNOWLEDGMENTS

We thank Jean Paul Viard and David Young for critical reviews of the manuscript and Thu-Huyen Nguyen and Eka Chakvetadze for clinical management. We also thank Elisette Maréchal-da-Silva and the patients who participated in the study.
of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 17:1121–1126.

41. Ruiz, L., J. Martínez-Picado, J. Romeu, R. Paredes, M. K. Zayat, S. Martí, E. Negredo, G. Sirera, C. Tural, and B. Clotet. 2000. Structured treatment interruption in chronically HIV-1-infected patients after long-term viral suppression. AIDS 14:397–403.

42. Skiest, D. J., P. Morrow, B. Allen, J. McKinsey, C. Crosby, B. Foster, and R. D. Hardy. 2004. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/µL. J. Acquir. Immune Defic. Syndr. 37:1351–1357.

43. Skiest, D. J., Z. Su, D. V. Havlir, K. R. Robertson, R. W. Croombs, P. Cain, T. Peterson, A. Krambrink, N. Jahed, D. McMahon, and D. M. Margolis. 2007. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS clinical trials group 5170. J. Infect. Dis. 195:1426–1436.

44. Tarwater, P. M., M. Parish, and J. E. Gallant. 2003. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin. Infect. Dis. 37:1541–1548.

45. Tebas, P., K. Henry, K. Mundy, S. Deeks, H. Valdez, C. Cohen, and W. G. Powderly. 2002. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J. Infect. Dis. 186:851–854.

46. Toulson, A. R., P. R. Harrigan, B. Yip, M. Harris, R. S. Hogg, W. Dong, K. V. Heath, and J. S. Montaner. 2004. Evaluation of outcomes following structured interruptions (STI) among patients with prior nadir CD4 cell counts >200 cells/mm³. Can. J. Infect. Dis. 15:S29A.

47. Tubiana, R., G. Carcelain, M. Vray, K. Gourlain, C. Dalban, A. Chermak, C. Rabian, D. Vittecoq, A. Simon, E. Bouvet, R. El Habib, D. Costagliola, V. Calvez, B. Autran, and C. Katlama. 2005. Therapeutic immunization with a human immunodeficiency virus (HIV) type-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter study (ANRS 094). Vaccine 23:4292–4301.

48. Reference deleted.

49. Wong, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV-1 despite prolonged suppression of plasma viremia. Science 278:1291–1295.

50. Yeni, P. G., S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Voderberg. 2002. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society—USA Panel. JAMA 288:222–235.

51. Younes, S. A., B. Yassine-Diabb, A. R. Dumont, M. R. Boullassel, Z. Grossman, J. P. Routy, and R. P. Sekaly. 2003. HIV-1 viremia prevents the establishment of interleukin-2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J. Exp. Med. 198:1909–1922.